One in Three Illicit Drug Samples Contain Unexpected Substances, Wedinos Finds

Overview

The Welsh Emerging Drug Identification Service Wedinos reports that more than one in three illicit drug samples did not contain the substance buyers believed they had purchased. Covering April 2025 to March 2026, Wedinos found that 36.6% of samples did not contain the expected substance, highlighting a market characterized by substitution and unknown contents. The findings raise concerns beyond Wales, with government bodies acknowledging new synthetic opioids and related substances in circulation. This brief summary from The Conversation (publisher) outlines how drug checking fits into harm reduction while emphasizing its limits when it comes to safety guarantees.

• Substitution is widespread across illicit drug markets, complicating identification by name, color, or packaging.
• New synthetic opioids, including orphine analogues, were identified alongside veterinary sedatives in heroin cases.
• Cannabinoid and other products sold illicitly contained synthetic cannabinoids (SCRAs) or other unexpected substances.
• Drug checking can reduce uncertainty and inform harm reduction, but it cannot guarantee safety or batch-to-batch consistency.

Overview

The Welsh Wedinos program has released a comprehensive assessment of illicit drug samples submitted between April 2025 and March 2026. The analysis reveals that 36.6% of samples did not contain the expected substance, and in more than a third of cases buyers were not given what they believed they were purchasing. This pattern of substitution demonstrates that the illicit drug market often involves products that differ from the seller’s claims in name, appearance, or packaging, making consumer cues a poor guide to content. The report situates these findings within a broader context of rapid emergence of new psychoactive substances and evolving supply chains, underscoring the complexity of the modern illicit drug market. The Conversation presents the core implications and the role of harm reduction strategies such as drug checking, while noting the limitations of testing as a safety guarantee.

Substitution and Market Dynamics

Wedinos data illustrate that buyers cannot rely on conventional identifiers like the drug name or packaging. Substitution efforts appear across multiple drug categories, from heroin to cannabinoids, with devices, brands, and online marketplaces contributing to a confusing marketplace. The Welsh Parliament has heard that some of these substances have been implicated in fatalities, and seven synthetic opioids have already been added to the Misuse of Drugs Act 1971 list of class A substances, signaling policy responses to the evolving risk landscape.

Orphine Analogues and Other Potent Substances

A notable finding is the emergence of a new group of synthetic opioids described as orphine analogues. These compounds, due to their high potency at small doses, raise particular risks for people who think they are using heroin but are exposed to a different, more powerful substance. In addition, Wedinos continues to identify nitazenes, an especially potent class of synthetic opioids, in submitted samples, illustrating how substitution continues to advance in parallel with evolving drug design and control measures.

Fake Medicines and Illicit Cannabinoids

The study also highlights counterfeit medicines bought through illicit routes, which can resemble legitimate diazepam or other drugs but contain unintended psychoactive substances. In the illicit cannabinoid market, about 43% of THC or related products submitted to Wedinos contained spice rather than the expected cannabinoid content, a development with rapid-onset adverse effects such as anxiety, panic, hallucinations, or seizures when vaped or ingested.

Public Health Implications and Harm Reduction

Drug checking is framed as an important harm reduction strategy, enabling identification of emerging substances and substitutions that may otherwise remain unseen. However, a single test of a given sample cannot guarantee the same content in other tablets or batches from the same seller. The article emphasizes that while drug checking can reduce uncertainty and inform safer practices, it should not be construed as a safety guarantee. The Wedinos findings also inform policy discussions, underscoring the need for robust monitoring and responsive regulation in the face of a shifting illicit market.

Context and Policy Response

The concerns extend beyond Wales. The UK parliament has noted deaths linked to orphine-like substances, and government authorities have begun classifying some of these compounds as controlled substances. Market substitutions may reflect multiple drivers, including price, availability, supply chains, policing, and legislative changes. Drug checking services are part of a broader harm reduction framework, supporting informed choices and risk reduction in tandem with ongoing drug policy adaptations.